A practical conversation on how biotechs can read RFPs differently, avoid the fluency trap, challenge assumptions, and choose vendors that can actually deliver.

Every biotech faces this moment: the RFP looks perfect, polished, aligned, convincing. But does it actually signal readiness?

In this episode, Seuss+ CEO Kieran Engels joins Julia Vassiliadou (F2G) to break down why a beautiful proposal can mislead sponsors, what real signals of vendor readiness look like, and how biotechs can tailor the selection process to avoid costly mistakes.

Together, they unpack:

• Why we confuse polish with capability
• The four signals that a vendor is genuinely ready
• How to challenge assumptions during bid defenses
• Why risk-based thinking (ICH E6 R3) should shape ...